Beyond Air

Beyond Air

Beyond Air is a commercial-stage medical device company headquartered in Garden City, New York, that went public via an initial public offering in 2016 and later uplisted to the Nasdaq under the ticker XAIR. The company acquired its core technology from a nitric oxide research group and was previously known as AIT Therapeutics before rebranding to Beyond Air in 2019. The firm's central focus is the LungFit platform, a device engineered to generate and deliver precise concentrations of nitric oxide on demand from ambient air, eliminating the need for bulky compressed cylinders. The company's lead product, LungFit PH, received FDA premarket approval in June 2022 for the treatment of persistent pulmonary hypertension of the newborn (PPHN) — an indication previously dominated by traditional cylinder-based systems from Mallinckrodt and Linde Healthcare. Beyond Air aims to replace these legacy systems in hospital neonatal intensive care units (NICUs) across the United States. A complementary pipeline targets nontuberculous mycobacterial (NTM) lung disease through a subsidiary, Beyond Cancer, which is developing ultra-high concentration nitric oxide as an immunotherapeutic agent in solid tumors. Beyond Air operates a direct commercial sales force launched post-FDA approval, targeting roughly 800 Level III and Level IV NICUs in the United States. Commercial rollout began in earnest in fiscal 2023, with initial hospital formulary approvals secured throughout the year. The company maintains its corporate headquarters in Garden City, New York, with manufacturing and research operations co-located there. In January 2024, the company announced pricing of an underwritten public offering of common stock, raising approximately $7.5 million in gross proceeds to support the LungFit commercial expansion and pipeline development. The company also holds a CE Mark approval for LungFit in Europe, though the primary commercial focus remains the United States. What structurally differentiates Beyond Air is that it is a public operating company masquerading under a name typically associated with a venture capital or private equity firm — a frequent source of misclassification in institutional databases. It carries no allocator mandates, no fund vehicles, and no external capital deployment program. The governance follows a standard public company model with a board chaired by CEO Steve Lisi, and subsidiaries are held as wholly owned corporate entities rather than fund portfolios. The lung-cancer immunotherapy subsidiary, Beyond Cancer, represents a vertical biotech play, not a portfolio diversification strategy.